Table 6.
Clinical trials targeting PDE4 in AD.
| Target Molecule | Clin Trial Gov | Type of Study | Status |
|---|---|---|---|
| PDE4 | |||
| PDE4 inhibitor, Crisaborole 2% topical small molecule |
NCT04023084 | Phase IV | Completed |
| PDE4 inhibitor, Crisaborole 2% topical small molecule |
NCT04214197 | Phase IV | Active, not recruiting |
| PDE4 inhibitor, Crisaborole 2% topical small molecule |
NCT04800185 | Early Phase I | Active, not recruiting |
| PDE4 inhibitor, Crisaborole 2% topical small molecule |
NCT03233529 | Phase II | Completed |
| PDE4 inhibitor, Roflumilast 0.15% ARQ-151 Active topical small molecule INTEGUMENT-I |
NCT04773587 | Phase III | Recruiting |
| PDE4 inhibitor, Roflumilast 0.15% ARQ-151 Active topical small molecule INTEGUMENT-II |
NCT04773600 | Phase III | Recruiting |
| PDE4 inhibitor, Roflumilast 0.05% ARQ-151 Active topical small molecule INTEGUMENT-PED |
NCT04845620 | Phase III | Recruiting |
| PDE4 inhibitor, Roflumilast 0.05–0.15% ARQ-151 Active topical small molecule INTEGUMENT-OLE |
NCT04804605 | Phase III | Recruiting |
| PDE4 inhibitor, Roflumilast 0.05% topical small molecule |
NCT01856764 | Phase II | Completed |
| PDE4 inhibitor, Hemay808 1%/3%/7% topical small molecule |
NCT04352595 | Phase II | Unknown |
| PDE4 inhibitor, GW842470X 3% Topical small molecule |
NCT00354510 | Phase II | Completed |
| PDE4 inhibitor, GW842470X 3% topical small molecule |
NCT00356642 | Phase I | Completed |
| PDE4 inhibitor, Apremilast 20 mg oral small molecule |
NCT00931242 | Phase II | Completed |
| PDE4 subtype with high PD4 affinity | |||
| PDE4 inhibitor, Orismilast 20 mg, 30 mg, or 40 mg oral small molecule |
NCT05469464 | Phase II | Recruiting |